-
Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition
Chen, S., Overberg, K., Ghouse, Z., Hollmann, M. W., Weber, N. C., Coronel, R. & Zuurbier, C. J., 1 May 2024, In: Biomedicine and Pharmacotherapy. 174, 116477.Research output: Contribution to journal › Article › Academic › peer-review
-
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2
Chen, S., Wang, Q., Bakker, D., Hu, X., Zhang, L., van der Made, I., Tebbens, A. M., Kovácsházi, C., Giricz, Z., Brenner, G. B. B., Ferdinandy, P., Schaart, G., Gemmink, A., Hesselink, M. K. C., Rivaud, M. R., Pieper, M. P., Hollmann, M. W., Weber, N. C., Balligand, J-L., Creemers, E. E., & 2 others, 2024, (E-pub ahead of print) In: Basic Research in Cardiology.Research output: Contribution to journal › Article › Academic › peer-review
-
SGLT2 independent effects of the SGLT2 inhibitor empagliflozin: Focus on the heart
Chen, S., 2024, 221 p.Research output: PhD Thesis › Phd-Thesis - Research and graduation internal
- All publications
